Genmab — April 2014
-
det er også mit bud, men vi er helt oppe imod målstregen lige nu - så den kan vel falde nårsomhelst!!!
-
Comparison of CDC activity using rituximab and ofatumumab revealed that the cytotoxic activity of ofatumumab was significantly higher than that of rituximab. http://onlinelibrary.wiley.com/doi/10.1111/bjh.12857/full
-
she was receiving ofatumumab, a humanized anti-CD20 monoclonal antibody approved by the Food and Drug Administration for the treatment of multidrug-resistant CLL, with efficacy against rituximab-resistant B-cell cancers.4 Therapy with ofatumumab produced a dramatic response in the patient's renal status
-
-
-
A phase 2 trial confirmed comparable high activity and safety of the O-FC (ofatumumab/fludarabine/cyclophosphamide) regimen as frontline treatment of previously untreated CLL. Investigators are moving forward with this regimen using the 1000-mg dose of ofatumumab.
-
-
-
rigtig flot luk i US med index oppe 2,5% - men mon ikke der er andet, der sætter dagsordenen på tirsdag....
-
det er vist kun i hans eget hoved, at der har været appelsiner i hans turban
-
det er jo lige det - hans tanker om GEN har intet med de sidste 6 ugers udvikling at gøre. Kursudviklingen har været rent markedsdrevet uden selskabsspecifikke nyheder overhovedet.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind